Form 4: Amgen SVP Rachna Khosla Reports Sale of 1,500 Shares of Company Stock

Amgen's Senior Vice President of Business Development, Rachna Khosla, reported the sale of 1,500 shares of common stock at a price of $289.68 per share, effective June 5, 2025.

Summary

• Rachna Khosla, Senior Vice President of Business Development at Amgen Inc. (AMGN), reported a transaction on June 5, 2025.
• The transaction involved the direct sale of 1,500 shares of Amgen common stock.
• The shares were sold at a price of $289.68 per share.
• Following this transaction, Ms. Khosla beneficially owns 8,162 shares of Amgen common stock directly.
• The reported shares include 112 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are credited on unvested Restricted Stock Units (RSUs) and are paid out in shares on a one-to-one basis according to the vesting schedule.

Sentiment

Score: 4

Explanation: The sale of 1,500 shares by a Senior Vice President, while not explicitly under a Rule 10b5-1 plan, is a routine disclosure for insider transactions. While insider selling can sometimes be viewed negatively, the size of this transaction relative to the company's market capitalization and the remaining beneficial ownership (8,162 shares) suggests a neutral to slightly negative sentiment rather than a strong negative signal.

Negatives

• Insider selling, even for personal financial planning, can sometimes be perceived negatively by the market as it might suggest a lack of confidence, although this is not always the case.
• The transaction was not explicitly indicated as being made pursuant to a Rule 10b5-1 trading plan, which could lead to greater scrutiny.

Risks

• Potential negative market perception if investors interpret the insider sale as a signal of reduced confidence in the company's future performance or as opportunistic selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This document reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape within the biotechnology and pharmaceutical sector.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially influencing sentiment or trading decisions regarding Amgen stock.

Key Dates

Keywords

Amgen, AMGN, Rachna Khosla, insider trading, Form 4, stock sale, beneficial ownership, SEC filing, corporate executive, biotechnology, pharmaceutical